Skip to content

Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients

Management of Prothrombin Times Outside the Therapeutic Range in Patients on Warfarin and With Otherwise Stable Levels

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00814177
Acronym
FORESPEAK-0
Enrollment
160
Registered
2008-12-24
Start date
2006-07-31
Completion date
2009-04-30
Last updated
2012-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Ischemic Stroke, Myocardial Infarction, Venous Thromboembolism

Keywords

warfarin, dosing, prothrombin time, Heart valve prosthesis

Brief summary

Warfarin is very effective for the prevention of blood clots (thrombosis). A test of coagulation, the prothrombin time (PT) is used to monitor the effect. The PT response to warfarin can fluctuate as a result of interactions with a large number of other drugs, food or herbal agents as well as for no apparent reason. Thus, frequent monitoring of the PT and dose adjustments according to the results are required. One third of our patients remain on the same maintenance dose over 6 months. However, also these patients sometimes have a PT result moderately outside the therapeutic range without any obvious explanation. Too short PTs may be due to missed dose(s) or more dark green vegetables in the diet. Too long PTs may be due to a course of antibiotic therapy or less dark green vegetables. Laboratory errors may also occur and can cause deviations in any direction. Most likely, unnoticed fluctuations in the PT occur as well between the time points of monitoring. There are no guidelines on how to manage the treatment in this situation but there are some typical behaviours. Behavior A: Some physicians simply let the patient continue with the same dose. It is extremely unlikely that the very temporary dose adjustment has any effect on the PT result 4 weeks later and this is a cosmetic procedure. Behavior B: Others recommend the patients to take ½ - 1 additional dose in case of short PT and to skip a dose or take half dose in case of long PT, and thereafter to continue with the usual dose. The investigators need to quickly correct the temporary aberration in order to avoid thrombotic or bleeding complications the next few days. This may seem like an issue of no importance. The investigators are however performing a series of studies to evaluate if these stable patients can be managed with blood tests less often than every 4 weeks. For that purpose it is important to know how often and why aberrant results occur, the implication and to what extent they can be ignored. The investigators hypothesis is that in patients with very stable PT-results and unchanged dose for 3 months, should continue with exactly the same maintenance dose, even when the result unexpectedly is slightly above or below the therapeutic range. The investigators believe that most of these occasional PT-results outside the therapeutic range are due to laboratory errors, perhaps missed doses by the patient or temporary change in diet or medications.

Detailed description

Setting: Thrombosis Service at HHS - General Hospital. This center monitors the warfarin treatment for 1300 patients in the region. These patient regularly go to a laboratory where they live. Test results (INR-results) are faxed to the Thrombosis Service, which calls the patient the same day to inform them of the results, how to continue dosing the warfarin and when to go for the following blood test.

Interventions

DRUGwarfarin

No change: Continue without any change in spite of prothrombin time outside the therapeutic range.

Sponsors

Hamilton Health Sciences Corporation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients on long-term warfarin (for prophylaxis of arterial embolism in patients with atrial fibrillation or mechanical heart valve replacement, or secondary prophylaxis after VTE) with a target INR of 2.0-3.0 or 2.5-3.5, 2. Anticoagulant therapy managed by the clinic (HHS - General Hospital) for at least 3 months prior to enrolment, and 3. Maintenance dose of warfarin unchanged for the previous 3 months or longer. 4. The INR result is outside the therapeutic range as follows: For those with target 2.0-3.0: Either an INR of 1.5-1.9 or an INR of 3.1-4.4. For those with target 2.5-3.5: Either an INR of 1.5-2.4 or an INR of 3.6-4.4.

Exclusion criteria

1. Age \<18 years, 2. Long-term (\>1 week) change in any other medication 3. Long-term (\>1 week) change in diet, especially regarding green vegetables. 4. Attending physician believes the patient is not suitable for the study (e.g. psychiatric disorder, history of non-compliance), 5. Failure to obtain telephone consent.

Design outcomes

Primary

MeasureTime frameDescription
Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks2 weeksThe number of patients with follow-up INRs within the therapeutic range was compared for patients with a single dose skipped/reduced/added versus patients with no change of dose.

Countries

Canada

Participant flow

Recruitment details

160 patients were randomized at a single center during the period July 2006 - August 2008

Pre-assignment details

The study was planned for the sample size of 326 but due to competing studies, testing new dosing algorithms, the inclusion rate was much lower than expected.

Participants by arm

ArmCount
No Change
Intervention Drug warfarin no change in the dose is performed
80
Change
Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level
80
Total160

Baseline characteristics

CharacteristicChangeNo ChangeTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
47 Participants59 Participants106 Participants
Age, Categorical
Between 18 and 65 years
33 Participants21 Participants54 Participants
Age Continuous67.1 years
STANDARD_DEVIATION 13.8
69.6 years
STANDARD_DEVIATION 11.4
68.4 years
STANDARD_DEVIATION 12.7
Region of Enrollment
Canada
80 participants80 participants160 participants
Sex: Female, Male
Female
34 Participants31 Participants65 Participants
Sex: Female, Male
Male
46 Participants49 Participants95 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
2 / 801 / 80
serious
Total, serious adverse events
0 / 800 / 80

Outcome results

Primary

Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks

The number of patients with follow-up INRs within the therapeutic range was compared for patients with a single dose skipped/reduced/added versus patients with no change of dose.

Time frame: 2 weeks

ArmMeasureValue (NUMBER)
No ChangeNumber of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks48 participants
ChangeNumber of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks45 participants

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026